In a packed session at the 75th Scientific Sessions of the American Diabetes Association, the lead investigator told attendees how a matchstick-size device delivered exenatide, producing lower blood ...
Intarcia Therapeutics anticipates filing for FDA approval at the end of the third quarter of 2016. At this year's ADA presentation, Julio Rosenstock, MD, said the insertion method for the novel ...
BOSTON, Oct. 1, 2014 -- Intarcia Therapeutics, Inc. today announced successful top-line results from two of its four phase 3 clinical trials for ITCA 650 (exenatide, delivered continuously once or ...
Intarcia Therapeutics, Inc. today announced the presentation of results from its first two phase 3 clinical trials (FREEDOM-1 and FREEDOM-1 HBL) of its late-stage investigational candidate ITCA 650 ...
DUROS continuous delivery of exenatide resulted in a reduced incidence and persistence of treatment-associated nausea. Nausea rates among patients receiving ITCA 650 at 40 mcg/day were similar to ...
Patients treated with ITCA 650 60mcg experienced superior reductions in HbA1c versus those treated with Januvia® (sitagliptin) 100mg (-1.5% versus -0.8%; p<0.001) ITCA 650 60mcg produced significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results